Anti-Fibrinolytic Drugs - Vietnam

Vietnam is projected to witness a significant growth in revenue within the Anti-Fibrinolytic Drugs market.
By the year 2024, the revenue is estimated to reach US$33.15m.
This growth is expected to continue with an annual growth rate, known as the Compound Annual Growth Rate (CAGR), of 5.72% from 2024 to 2029.
Consequently, by 2029, the market volume in Vietnam is projected to reach US$43.78m.
When comparing the Anti-Fibrinolytic Drugs market globally, it is worth noting that United States is expected to generate the highest revenue.
In 2024, United States is projected to generate a revenue of US$9.86bn.
Vietnam has seen a surge in the demand for anti-fibrinolytic drugs due to the increasing number of patients with bleeding disorders.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The demand for Anti-Fibrinolytic Drugs in Vietnam has been increasing steadily in recent years.

Customer preferences: Vietnam has a rapidly aging population, and as a result, there has been an increase in the prevalence of age-related diseases such as cardiovascular diseases, which require the use of Anti-Fibrinolytic Drugs. Additionally, the rise in the number of surgeries being performed in the country has also contributed to the growth of the market.

Trends in the market: The Anti-Fibrinolytic Drugs market in Vietnam is expected to continue growing due to the increasing demand for these drugs. The market is also being driven by the introduction of new drugs and the expansion of the indication of existing drugs. Furthermore, the increasing availability of healthcare services and the growing awareness of the benefits of these drugs are also contributing to the growth of the market.

Local special circumstances: Vietnam's healthcare system is still developing, with a large portion of the population not having access to quality healthcare services. Additionally, the country's healthcare infrastructure is not yet fully equipped to handle the increasing demand for healthcare services. These factors are likely to impact the growth of the Anti-Fibrinolytic Drugs market in Vietnam.

Underlying macroeconomic factors: Vietnam's economy has been growing steadily in recent years, with the country's GDP increasing at an average rate of 6-7% per year. This growth is expected to continue, which will likely lead to an increase in the demand for healthcare services, including Anti-Fibrinolytic Drugs. Additionally, the government has been investing in the healthcare sector, which is likely to further drive the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.